Welcome to our dedicated page for Moolec Science news (Ticker: MLEC), a resource for investors and traders seeking the latest updates and insights on Moolec Science stock.
Moolec Science SA (MLEC) is a science-based ingredient company revolutionizing food production by leveraging Molecular Farming technology to produce real animal proteins in plants. This innovative method integrates the cost structure of plant-based production with the nutritional and functional benefits of animal proteins, offering a solution that meets the growing demand for sustainable, high-quality food ingredients.
Core Business and Technological Innovation
At its core, Moolec Science is dedicated to reengineering traditional food sources by embedding animal protein genes into plants such as soybean, safflower, and pea. This process creates ingredients that possess the organoleptic and nutritional characteristics of animal proteins, while ensuring the scalability and affordability of plant-based solutions. The company stands out by utilizing advanced biotechnological methods underpinned by rigorous scientific research and a longstanding commitment to innovation.
Diverse Product Portfolio
The company features a wide array of products designed to address various segments of the food and dietary supplementation markets:
- TSP Valorasoy: A soy protein product that mimics the texture and fibrousness of meat, catering to the rising demand for plant-based meat alternatives.
- GLASO: A safflower oil rich in gamma-linolenic acid, offering an exceptional nutritional profile for functional foods, cosmetics, and animal nutrition applications.
- SPC2: A plant-based chymosin produced via Molecular Farming, which has potential applications in dairy processing and cheese production.
- Piggy Sooy: An innovative, genetically engineered soybean enriched with porcine myoglobin, designed to bridge the gap between plant-based and conventional animal protein sources.
- Additional extracts and novel ingredients driven by cutting-edge biotechnology and continuous R&D efforts.
Market Position and Strategic Milestones
Moolec Science has established itself within a competitive landscape marked by rapidly advancing alternative protein solutions. Its portfolio is reinforced by key regulatory approvals such as those granted by USDA-APHIS, along with a robust international patent portfolio, which collectively underscore the scientific credibility of its molecular farming processes. Strategic partnerships and offtake agreements with global consumer packaged goods companies further solidify its commercial position and ensure a controlled, traceable supply chain.
Operational Expertise and Global Reach
The strength of Moolec Science is amplified by a diverse team of Ph.D.s and industry experts who steer the company’s research, development, and global operations. With activities spanning North America, Europe, and South America, the company leverages agronomic efficiencies and innovative biotechnological platforms to deliver breakthrough products that meet stringent quality and regulatory standards.
Competitive Differentiation and Industry Impact
In an industry where many companies focus solely on either traditional plant-based or cell-based methods, Moolec Science offers a unique hybrid approach. Its ability to produce ingredients that balance the benefits of both animal and plant sources allows it to address nutritional challenges more effectively while maintaining environmental sustainability. This nuanced approach not only positions the company as a credible innovator in industrial biotechnology but also enhances its stature among investors and industry analysts seeking reliable, science-backed growth strategies.
Overall, Moolec Science SA stands as a pivotal entity in the evolution of food technology, delivering comprehensive solutions that combine scientific innovation, sustainability, and operational excellence. Its integrated approach to Molecular Farming is setting new benchmarks in the food ingredient industry, making it a significant point of reference for stakeholders across the market.
Moolec Science SA (NASDAQ:MLEC) has received a Nasdaq Staff Determination Letter on March 11, 2025, indicating non-compliance with listing requirements as its stock price remained below $1.00 for over 30 consecutive business days since September 10, 2024. The company is not eligible for a second 180-day compliance period due to not meeting the $5,000,000 minimum stockholders' equity requirement.
On March 13, 2025, Moolec appealed the determination and plans to present a compliance strategy involving a reverse share split. The appeal temporarily halts any delisting actions. The Board of Directors has resolved to convene an extraordinary shareholders meeting to vote on the reverse share split. Without securing an extension from the Hearings Panel or achieving compliance, the company's ordinary shares and warrants face potential delisting from Nasdaq.
Moolec Science SA (NASDAQ:MLEC) has received USDA approval for the first genetically modified pea in history. The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) completed its Regulatory Status Review for Moolec's genetically engineered peas that produce iron through bovine meat proteins. This marks Moolec's third USDA-APHIS regulatory clearance in 18 months, following approvals for genetically engineered safflower and soybean.
The GE peas produce high yields of bovine myoglobin, boosting iron content and offering a plant-based iron source. This innovation has the potential to impact both the food ingredient market and the $65 billion pea industry. The approval validates Moolec's strategic approach and commitment to sustainable food production through science and innovation.
Moolec Science SA (NASDAQ:MLEC) reported its Business Update for Q4 FY2024 ended June 30, 2024. Key highlights include:
1. GLASO™: Secured an offtake agreement with a major global CPG food and pet food company and an R&D collaboration with Bunge. Significant advancements in upstream and downstream processes.
2. Piggy Sooy™: Field trials in three US locations progressing for product development, seed increase, and regulatory data gathering.
3. TSP Valorasoy™: Trials for enhanced Valorasoy 2.0 products showed encouraging results.
4. Financials: Revenue & other income of ~$6M for FY 2024, driven by soy protein ingredient business. Prudent cash burn in line with company growth.
The company highlighted the USDA-APHIS approval for PiggySooy™ as a pivotal moment in Molecular Farming. Moolec is preparing for the commercialization of GLASO™ and advancing its product pipeline.
Moolec Science SA (NASDAQ:MLEC), a science-based food ingredient company, has announced it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on October 2, 2024, before market open. The company will host a live Conference Call and webcast on the same day at 08:30 AM ET.
The call will feature CEO Gastón Paladini, CFO José López Lecube, and Chief Science Officer Amit Dhingra. It will include a presentation viewable during the webcast, with a replay and PDF version available afterwards on Moolec's Investor Relations website.
Participants can join via the provided Zoom link or dial-in numbers. The webinar ID is 915 9750 1131, with passcode 799765. International dial-in numbers are also available.
Moolec Science SA (NASDAQ:MLEC), a food ingredient company, received a Nasdaq Bid Price Letter due to its closing bid price falling below $1.00 for 30 consecutive business days. This violates Nasdaq Listing Rule 5550(a)(2). The company has until March 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days. If unsuccessful, Moolec may be eligible for an additional 180-day compliance period, provided it meets other Nasdaq Capital Market listing requirements. Failure to comply could result in delisting. Moolec is committed to resolving the deficiency and maintaining its Nasdaq listing.
Moolec Science SA (NASDAQ:MLEC) has announced the upcoming harvest of its genetically engineered plant-grown products GLASO™ and Piggy Sooy™ in October 2024. The GLASO™ campaign in Idaho covers 600 acres and is expected to yield 300-400 tons of high-GLA safflower seeds. Moolec has secured an offtake agreement with a major global CPG company for GLASO™, targeting the US market in 2025. Piggy Sooy™ field trials are being conducted in Ohio, Missouri, and Iowa for product development, seed increase, and regulatory data gathering. Moolec recently obtained USDA-APHIS approval for Piggy Sooy™ cultivation, marking a significant milestone in Molecular Farming. The company aims to provide sustainable solutions in agriculture and biotechnology, with Piggy Sooy™ potentially producing pork meat proteins equivalent to 10 pigs per acre while reducing environmental impact.
Moolec Science SA (NASDAQ:MLEC) has signed a three-year offtake agreement with a major global consumer packaged goods and pet food company for its GLASO™ product, a high-GLA safflower oil. The agreement covers US territory with an initial estimated volume of 50 tons for 2025. GLASO™ contains almost 3 times more GLA than conventional sources, making it the most concentrated GLA oil available.
Moolec has also secured agreements with farmers for safflower cultivation and an industrial partner for downstream processing, ensuring a controlled supply chain. This milestone demonstrates Moolec's ability to scale production and meet growing demand for sustainable nutritional ingredients.
Moolec Science (NASDAQ:MLEC) has released its business update for the third quarter of Fiscal Year 2024, ending March 31, 2024. Key highlights include the USDA-APHIS regulatory approval of their patented soybean product, Piggy Sooy™, and progress in the GLASO™ safflower platform. Financially, normalized revenues and other income increased by approximately $1.3 million year-over-year due to the consolidation of the soy-protein ingredient business. However, R&D, administrative, and other expenses rose to $2.3 million, a 68% year-over-year increase, largely due to non-cash items. Operational cash utilization for the quarter was around $2.6 million, with $1.4 million allocated to reducing accounts payable. CEO Gastón Paladini and CFO José López Lecube expressed optimism about the company's achievements and future prospects.
Moolec Science (NASDAQ: MLEC), a company specializing in Molecular Farming to produce animal proteins in plants, will release its Third Quarter Fiscal Year 2024 Business Update on May 30, 2024, before market opening.
CEO Gastón Paladini, CFO José López Lecube, and CSO Amit Dhingra will host a live conference call at 08:30 a.m. ET the same day, followed by a Q&A session. The conference call will feature a presentation available during the webcast, with a replay and PDF version accessible two hours post-event on the company's Investor Relations website.
Moolec Science SA (NASDAQ: MLEC) announced the granting of a patent in the United States for its SPC2 product produced in safflower with Molecular Farming technology. This patent provides exclusivity until 2041, showcasing Moolec's innovative approach in the industrial biotech sector. The technology involves safflower plants engineered with DNA sequences to enhance bovine chymosin expression, paving the way for new proteins and products. Moolec's Chief Science Officer highlighted the significance of this patent in expanding opportunities for the company's safflower platform and driving innovation in sustainable biotechnology.
FAQ
What is the current stock price of Moolec Science (MLEC)?
What is the market cap of Moolec Science (MLEC)?
What is the core focus of Moolec Science?
How does the company generate revenue?
What are the main products offered by Moolec Science?
How does Molecular Farming benefit the production process?
What regulatory approvals has Moolec Science achieved?
In which markets does the company operate?
How does Moolec Science maintain product quality?
How does the company differentiate itself from competitors?
